MedTrace Logo

Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

NCT01435460 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2012-03-13

Study results available
· View outcomes & findings →

Summary

This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).

Conditions

  • Seasonal Allergic Conjunctivitis

Interventions

DRUG

Loteprednol etabonate 0.2%

1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.

DRUG

Olopatadine 0.1%

1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Esther Chu · Bausch & Lomb Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-04-30
Completion
2011-05-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01435460 on ClinicalTrials.gov